Skip to main content
SpringerLink
Log in

Defining Surgical Indications for Type I Gastric Carcinoid Tumor

  • Endocrine Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Most gastric carcinoid tumors (GC) (type I) occur in association with achlorhydria, hypergastrinemia, atrophic gastritis and exhibit low-grade histopathology. The management of this indolent disease is controversial. The aim of this study was to evaluate endoscopic surveillance (ES) compare with surgical resection (SR) for type I GC.

Methods

Between 1985 and 2007, 65 patients with type I GC were identified. Data analysis included: demographics, biochemical and endoscopic assessment, type of operation performed, and pathologic evaluation. The primary endpoints were disease-specific survival (DSS) in both groups and recurrence-free survival (RFS) in SR patients.

Results

Median follow-up was 30 months (range 1–176 months); most patients were female (83%) with median age of 58 years (range 29–91 years). Type I GC was diagnosed by evidence of hypergastrinemia and/or positive autoimmune antibodies with histopathologic confirmation. Patients underwent ES with polypectomy (n = 46) or gastric resection (n = 19). SR was performed with larger tumor size, increased depth of invasion, and solitary tumors. Although the 5-year RFS in SR patients was 75%, the DSS in both groups was 100%. However, concomitant adenocarcinoma was identified in 4/19 resected cases; 2/4 were detected on preoperative biopsies. All cases with coexisting gastric adenocarcinoma had larger carcinoid tumors and more advanced carcinoid disease.

Conclusions

The DSS is excellent for type I GC patients treated with either ES or SR. SR should be considered with more advanced carcinoid disease given its association with an increased risk of adenocarcinoma. ES is appropriate to assess both the status of carcinoid disease and dysplasia or adenocarcinoma that can develop in association with type I GC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934–59.

    Article  PubMed  Google Scholar 

  2. Mulkeen A, Cha C. Gastric carcinoid. Curr Opin Oncol. 2004;17:1–6.

    Article  Google Scholar 

  3. Rindi G, Bordi C, Rappel S, et al. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg. 1996;20(2):168–72.

    Article  CAS  PubMed  Google Scholar 

  4. Rindi G, Luinetti O, Cornaggia M, et al. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology. 1993;104(4):994–1006.

    CAS  PubMed  Google Scholar 

  5. Smith AM, Watson SA, Caplin M, et al. Gastric carcinoid expresses the gastrin autocrine pathway. Br J Surg. 1998;85(9):1285–9.

    Article  CAS  PubMed  Google Scholar 

  6. Bordi C, Yu JY, Baggi MT, et al. Gastric carcinoids and their precursor lesions. A histologic and immunohistochemical study of 23 cases. Cancer. 1991;67(3):663–72.

    Article  CAS  PubMed  Google Scholar 

  7. Borch K, Ahren B, Ahlman H, et al. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg. 2005;242(1):64–73.

    Article  PubMed  Google Scholar 

  8. Akerstrom G. Management of carcinoid tumors of the stomach, duodenum, and pancreas. World J Surg. 1996;20(2):173–82.

    Article  CAS  PubMed  Google Scholar 

  9. Schindl M, Kaserer K, Niederle B. Treatment of gastric neuroendocrine tumors: the necessity of a type-adapted treatment. Arch Surg. 2001;136(1):49–54.

    Article  CAS  PubMed  Google Scholar 

  10. Gonzalez Ramirez A, Lopez Roses L, Santos Blanco E, et al. Multiple gastric carcinoid tumors: endoscopic management. J Clin Gastroenterol. 1996;23(1):75–7.

    Article  CAS  PubMed  Google Scholar 

  11. Ichikawa J, Tanabe S, Koizumi W, et al. Endoscopic mucosal resection in the management of gastric carcinoid tumors. Endoscopy. 2003;35(3):203–6.

    Article  CAS  PubMed  Google Scholar 

  12. Hakanson R, Ding XQ, Norlen P, Lindstrom E. CCK2 receptor antagonists: pharmacological tools to study the gastrin-ECL cell-parietal cell axis. Regul Pept. 1999;80(1–2):1–12.

    Article  CAS  PubMed  Google Scholar 

  13. Kidd M, Modlin IM, Black JW, et al. A comparison of the effects of gastrin, somatostatin and dopamine receptor ligands on rat gastric enterochromaffin-like cell secretion and proliferation. Regul Pept. 2007;143(1–3):109–17.

    Article  CAS  PubMed  Google Scholar 

  14. Dakin GF, Warner RR, Pomp A, et al. Presentation, treatment, and outcome of type 1 gastric carcinoid tumors. J Surg Oncol. 2006;93(5):368–72.

    Article  PubMed  Google Scholar 

  15. Bentrem D, Gerdes H, Tang L, et al. Clinical correlation of endoscopic ultrasonography with pathologic stage and outcome in patients undergoing curative resection for gastric cancer. Ann Surg Oncol. 2007;14(6):1853–9.

    Article  PubMed  Google Scholar 

  16. Modlin IM, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol. 2004;99(1):23–32.

    Article  PubMed  Google Scholar 

  17. Hou W, Schubert ML. Treatment of gastric carcinoids. Curr Treat Options Gastroenterol. 2007;10(2):123–33.

    Article  PubMed  Google Scholar 

  18. Jordan PH Jr, Barroso A, Sweeney J. Gastric carcinoids in patients with hypergastrinemia. J Am Coll Surg. 2004;199(4):552–5.

    Article  PubMed  Google Scholar 

  19. Modlin IM, Gilligan CJ, Lawton GP, et al. Gastric carcinoids The Yale Experience. Arch Surg 1995;130(3):250–5; discussion 255–6.

    CAS  PubMed  Google Scholar 

  20. Thomas RM, Baybick JH, Elsayed AM, Sobin LH. Gastric carcinoids. An immunohistochemical and clinicopathologic study of 104 patients. Cancer. 1994;73(8):2053–8.

    Article  CAS  PubMed  Google Scholar 

  21. Wiedenmann B, Jensen RT, Mignon M, et al. Preoperative diagnosis and surgical management of neuroendocrine gastroenteropancreatic tumors: general recommendations by a consensus workshop. World J Surg. 1998;22(3):309–18.

    Article  CAS  PubMed  Google Scholar 

  22. Rindi G, Azzoni C, La Rosa S, et al. ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology. 1999;116(3):532–42.

    Article  CAS  PubMed  Google Scholar 

  23. Kidd M, Hinoue T, Eick G, et al. Global expression analysis of ECL cells in Mastomys natalensis gastric mucosa identifies alterations in the AP-1 pathway induced by gastrin-mediated transformation. Physiol Genomics. 2004;20(1):131–42.

    Article  CAS  PubMed  Google Scholar 

  24. Kidd M, Modlin IM, Eick GN, et al. Role of CCN2/CTGF in the proliferation of Mastomys enterochromaffin-like cells and gastric carcinoid development. Am J Physiol Gastrointest Liver Physiol. 2007;292(1):G191–200.

    Article  CAS  PubMed  Google Scholar 

  25. Tang LH, Modlin IM, Lawton GP, et al. The role of transforming growth factor alpha in the enterochromaffin-like cell tumor autonomy in an African rodent mastomys. Gastroenterology 1996;111(5):1212–23.

    Article  CAS  PubMed  Google Scholar 

  26. Modlin IM, Lye KD, Kidd M. Carcinoid tumors of the stomach. Surg Oncol. 2003;12(2):153–72.

    Article  PubMed  Google Scholar 

  27. Eckhauser FE, Lloyd RV, Thompson NW, et al. Antrectomy for multicentric, argyrophil gastric carcinoids: a preliminary report. Surgery. 1988;104(6):1046–53.

    CAS  PubMed  Google Scholar 

  28. D’Adda T, Pilato FP, Sivelli R, et al. Gastric carcinoid tumor and its precursor lesions. Ultrastructural study of a case before and after antrectomy. Arch Pathol Lab Med. 1994;118(6):658–63.

    PubMed  Google Scholar 

  29. Hirschowitz BI, Griffith J, Pellegrin D, Cummings OW. Rapid regression of enterochromaffinlike cell gastric carcinoids in pernicious anemia after antrectomy. Gastroenterology. 1992;102(4 Pt 1):1409–18.

    CAS  PubMed  Google Scholar 

  30. Guillem P, Vlaeminck-Guillem V, Leteurtre E, et al. Fundic endocrine tumors and atrophic gastritis: the value of antrectomy. Gastroenterol Clin Biol. 2002;26(8–9):782–5.

    PubMed  Google Scholar 

  31. Wangberg B, Grimelius L, Granerus G, et al. The role of gastric resection in the management of multicentric argyrophil gastric carcinoids. Surgery. 1990;108(5):851–7.

    CAS  PubMed  Google Scholar 

  32. Hamilton SR, Aaltonen LA. World Health Organization classification of tumors, pathology and genetics of tumors of the digestive system. Lyon: IARC; 2000.

    Google Scholar 

  33. Ronellenfitsch U, Strobel P, Schwarzbach MH, et al. A composite adenoendocrine carcinoma of the stomach arising from a neuroendocrine tumor. J Gastrointest Surg. 2007;11(11):1573–5.

    Article  PubMed  Google Scholar 

  34. Pidoto RR, Piquard A, Fama F, Saint Marc O. Lymph node metastasis from gastric carcinoid tumors occurring concomitantly with gastric adenocarcinomas and atrophic gastritis. J Gastrointest Surg. 2006;10(3):402–6.

    Article  PubMed  Google Scholar 

  35. Waldum HL, Aase S, Kvetnoi I, et al. Neuroendocrine differentiation in human gastric carcinoma. Cancer. 1998;83(3):435–44.

    Article  CAS  PubMed  Google Scholar 

  36. Hsing AW, Hansson LE, McLaughlin JK, et al. Pernicious anemia and subsequent cancer. A population-based cohort study. Cancer. 1993;71(3):745–50.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgement

This work was partially supported by Raymond and Beverley Sackler Foundation.

Author information

Authors and Affiliations

  1. Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    Rebecca A. Gladdy MD, PhD, Vivian E. Strong MD, Daniel Coit MD, Peter J. Allen MD & Murray F. Brennan MD

  2. Department of Gastroenterology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    Hans Gerdes MD

  3. Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    Jinru Shia MD, David S. Klimstra MD & Laura H. Tang MD, PhD

Authors
  1. Rebecca A. Gladdy MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vivian E. Strong MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniel Coit MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter J. Allen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hans Gerdes MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jinru Shia MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. David S. Klimstra MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Murray F. Brennan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Laura H. Tang MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laura H. Tang MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gladdy, R.A., Strong, V.E., Coit, D. et al. Defining Surgical Indications for Type I Gastric Carcinoid Tumor. Ann Surg Oncol 16, 3154–3160 (2009). https://doi.org/10.1245/s10434-009-0687-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-009-0687-y

Keywords

Search

Navigation